Vertex Pharmaceuticals Inc

Premium Exclusive: These stocks have momentum on their side yet still look undervalued by our metrics.

Vertex Pharmaceutical's monopoly in the cystic fibrosis market forms the basis of our narrow-moat rating, and we expect that moat to continue to grow.

These stocks have gained twice as much as the S&P 500 in 2017 yet remain undervalued according to our metrics.

The shares currently look undervalued ahead of further drug approval.

Trump's review of the Clean Power Plan shouldn't alter the long-term move toward natural gas and renewables. Plus, active management shakeup at BlackRock, and Vertex soars after trial.

Shares soared following favorable news from the narrow-moat drugmaker's pivotal trials, yet we see further upside.

The market is underestimating Vertex's entrenched position in the cystic fibrosis market supported by a robust pipeline of next-generation products.

In a year of unexpected events, U.S. stocks rose again with small caps outperforming for the first time since 2013.

We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Oct. 15.

Despite a slowdown in Orkambi refills, this narrow-moat drugmaker's burgeoning cystic fibrosis portfolio should create a dominant franchise in this lucrative rare disease market.

A trio of Morningstar analysts share their outlooks for and opportunities in the healthcare, consumer, and basic materials sectors.

Whether you need to fill a hole in your retirement portfolio or want to find a world-class company at a bargain-basement stock price, a trio of Morningstar specialists share their shopping lists of topnotch candidates.

Morningstar's Russ Kinnel, Ben Johnson, and Elizabeth Collins discuss their favorite investment ideas among mutual funds, ETFs, and stocks.

With an increasingly dominant position in cystic fibrosis, Vertex’s competitive position is strong, and the stock's sell-off has been unwarranted.

A strong competitive position in the cystic fibrosis market gives the firm a narrow moat.

Some high-quality biotech names are trading at substantial discounts, as the market reacts to near-term concerns over pricing and biosimilar competition.

Although we're in the early innings of the personal-medication revolution, the stock prices of most biotech companies are sky-high.

These managers could be among those considered for the 2014 award.

Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.

We dive into the process for adding companies and booting them from the iconic index.